澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

RADIOPHARM THERANOSTICS LTD

0.008

-0.001-11.11%

成交量：2,001.54萬

成交額：16.60萬

市值：3,470.04萬

市盈率：-0.45

高：0.009

開：0.009

低：0.008

收：0.009

52周最高：0.040

52周最低：0.008

股本：43.38億

流通股本：33.43億

量比：5.25

換手率：0.60%

股息：- -

股息率：- -

每股收益(TTM):-0.018

每股收益(LYR):-0.018

淨資產收益率：-174.71%

總資產收益率：-44.61%

市淨率：1.41

市盈率(LYR):-0.45

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

Radiopharm Theranostics：所有可評估胰腺癌患者均觀察到顯著腫瘤攝取

Radiopharm Theranostics：Rad301受試者安全性良好，生物分佈表現積極

Radiopharm Theranostics公布Rad301在胰腺導管腺癌患者中的I期影像試驗積極數據

Radiopharm Theranostics年度初步虧損擴大50.3% 截至2026年6月30日財年虧損達5515萬澳元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/RAD.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RAD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","market":"AU","secType":"STK","nameCN":"RADIOPHARM THERANOSTICS LTD","latestPrice":0.008,"timestamp":1789107120000,"preClose":0.009,"halted":0,"volume":20015355,"delay":0,"changeRate":-0.11111111111111102,"nameEN":"RADIOPHARM THERANOSTICS LTD","floatShares":3342779849,"shares":4337549000,"eps":-0.0179,"marketStatus":"休市中","change":-0.001,"latestTime":"09-11 16:12:00 AEST","open":0.009,"high":0.009,"low":0.008,"amount":165989,"amplitude":0.111111,"askPrice":0.009,"askSize":3317701,"bidPrice":0.008,"bidSize":4152419,"shortable":3,"etf":0,"ttmEps":-0.0179,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.009,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":5.248799982810243,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RAD.AU","preClose":0.009,"auctionPrice":0.009,"auctionVolume":800000,"auction":3,"marketStatus":"盘后竞价","timestamp":1789106425280}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RAD.AU\",,,,,undefined,":{"symbol":"RAD.AU","floatShares":3342779849,"roa":"-44.61%","roe":"-174.71%","lyrEps":-0.0179,"volumeRatio":5.248799982810243,"shares":4337549000,"dividePrice":0,"high":0.009,"amplitude":0.111111,"preClose":0.009,"low":0.008,"week52Low":0.008,"pbRate":"1.41","psRate":"2.57","week52High":0.04,"institutionHeld":0,"latestPrice":0.008,"committee":0.111741,"eps":-0.0179,"divideRate":0,"volume":20015355,"delay":0,"ttmEps":-0.0179,"open":0.009,"prevYearClose":0.025,"prevWeekClose":0.009,"prevMonthClose":0.01,"prevQuarterClose":0.019,"fiveDayClose":0.009,"twentyDayClose":0.011,"sixtyDayClose":0.02,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAD.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAD.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAD.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1106926898","title":"Radiopharm Theranostics：所有可評估胰腺癌患者均觀察到顯著腫瘤攝取","url":"https://stock-news.laohu8.com/highlight/detail?id=1106926898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106926898?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952276,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics传来重磅消息——在其相关研究中，所有可评估的胰腺癌患者均表现出了显著的肿瘤摄取现象。这一发现无疑为胰腺癌诊疗领域投下了一枚震撼弹。据悉，该结果可能为后续更精准的靶向治疗与成像策略奠定关键基础，其临床意义不容小觑。业界普遍关注，这一积极信号能否顺利转化为切实可行的治疗方案，从而惠及广大患者群体。市场对此消息的初步反应亦颇为敏感，投资者正密切观望后续的详细数据披露与监管审批动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAD.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124219327","title":"Radiopharm Theranostics：Rad301受試者安全性良好，生物分佈表現積極","url":"https://stock-news.laohu8.com/highlight/detail?id=1124219327","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124219327?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:11","pubTimestamp":1788952273,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics公司宣布，其候选药物Rad301在临床试验中展现出令人鼓舞的结果。所有接受该药物剂量给药的研究对象均表现出良好的安全性，同时生物分布数据也呈现有利态势。这一积极进展为公司研发管线注入了新的信心，Rad301作为潜在治疗方案的可行性与耐受性获得了初步验证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141615521","title":"Radiopharm Theranostics公布Rad301在胰腺導管腺癌患者中的I期影像試驗積極數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1141615521","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141615521?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:02","pubTimestamp":1788951758,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics今日宣布，其候选药物Rad301在针对胰腺导管腺癌患者的I期影像学临床试验中取得了令人振奋的积极结果。这一进展为该公司在肿瘤精准诊断领域的布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172086213","title":"Radiopharm Theranostics年度初步虧損擴大50.3% 截至2026年6月30日財年虧損達5515萬澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=1172086213","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172086213?lang=zh_tw&edition=fundamental","pubTime":"2026-08-28 14:10","pubTimestamp":1787897411,"startTime":"0","endTime":"0","summary":"Radiopharm Theranostics（澳大利亚证券交易所代码：RAD.AU）披露了截至2026年6月30日的年度初步财务业绩，数据显示该公司年度应占亏损同比扩大50.3%，达到5515万澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAD.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RAD.AU\",params:#limit:6,delay:true,,,undefined,":[]}}